-- FactSetが調査したアナリストによると、AnaptysBio（ANAB）の平均投資判断は「買い」、平均目標株価は54.85ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Price: $50.85, Change: $-0.97, Percent Change: -1.87%
Related Articles
Asia
FINEOS Reports Higher Q1 Customer Cash Receipts
FINEOS (ASX:FCL) reported first-quarter customer cash receipts of 56.5 million euros, up 9.3% year-on-year, driven by subscription fee revenues invoiced in January, according to a Monday Australian bourse filing.The company recorded customer cash receipts of 51.7 million euros for the three months ending March 31, 2025, an earlier filing showed.Exchange rate movements during the quarter had a positive impact of 1 million euros on the cash balance.The company's full-year revenue guidance remains in the range of 147 million euros to 152 million euros.The company's shares fell 1% in recent Monday trade.
$ASX:FCL
Asia
Changyu Holding Prices IPO at 13.86 Yuan
Changyu Holding (SHA:603407) priced its initial public offering on the Shanghai Stock Exchange of 41 million shares at 13.86 yuan apiece to raise 568.3 million yuan, according to a weekend filing on the bourse.Proceeds will be invested in the company's zirconium oxychloride and deep-processing project, a nylon elastomer products project, and a bioceramics and functional ceramics products project.
$SHA:603407
Asia
Shaanxi Coal Industry's 2025 Profit Drops 25%, Revenue Falls 14%; Shares Down 4%
Shaanxi Coal Industry's (SHA:601225) net profit attributable to shareholders in 2025 dropped 25% year on year to 16.8 billion yuan, or 1.73 yuan per share, according to a Saturday filing on the Shanghai bourse.The coal miner's share dropped 4% during the morning trade.The attributable profit a year earlier was 22.4 billion yuan, or 2.31 yuan per share.Operating revenue fell 14% to 158.2 billion yuan from 184.1 billion yuan in the previous year.
$SHA:601225